Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase

Journal of Medicinal Chemistry

Volumn 47, Issue 27, 2004, Pages 6921-6934

  Rückle, Thomas ^a   Biamonte, Marco ^a,c   Grippi Vallotton, Tania ^a   Arkinstall, Steve ^b   Cambet, Yves ^a   Camps, Montserrat ^a   Chabert, Christian ^a   Church, Dennis J ^a   Halazy, Serge ^a   Jiang, Xuliang ^b   Martinou, Isabelle ^a   Nichols, Anthony ^a   Sauer, Wolfgang ^a   Gotteland, Jean Pierre ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b Serono Repro Biology Institute   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (BENZOYLAMINOMETHYL)THIOPHENE SULFONAMIDE; 2 (BENZOYLAMINOMETHYL)THIOPHENE SULFONAMIDE BENZOTRIAZOLE; 4 BENZOTRIAZOLYLPIPERIDINESULFONAMIDE; 4 CHLORO N THIOPHEN 2 YLMETHYLBENZAMIDE; N [5 (4 BENZOTRIAZOL 1 YLPIPERIDINE 1 SULFONYL)THIOPHEN 2 YL METHYL] 4 CHLOROBENZAMIDE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; NERVE CELL NECROSIS; NEWBORN; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELLS, CULTURED; DRUG DESIGN; ENZYME INHIBITORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEUROPROTECTIVE AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THIOPHENES;

EID: 19944429605     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031112e     Document Type: Article

References (30)

1. Cobb, M. H.; Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem. 1995, 270, 14843-14846.
2. Minden, A.; Karin, M. Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta 1997, 1333, F85-104.
3. Barr, R. K.; Bogoyevitch, M. A. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int. J. Biochem. Cell Biol. 2001, 33, 1047-1063.
4. Gupta, S.; Barrett, T.; Whitmarsh, A. J.; Cavanagh, J.; Sluss, H. K.; Derijard, B.; Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996, 15, 2760-2770.
5. Hibi, M.; Lin, A.; Smeal, T.; Minden, A.; Karin, M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 1993, 7, 2135-2148.
6. Whitmarsh, A. J.; Shore, P.; Sharrocks, A. D.; Davis, R. J. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995, 269, 403-407.
7. Chow, C. W.; Rincon, M.; Cavanagh, J.; Dickens, M.; Davis, R. J. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 1997, 278, 1638-1641.
8. Milne, D. M.; Campbell, L. E.; Campbell, D. G.; Meek, D. W. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J. Biol Chem. 1995, 270, 5511-5518.
9. Mohit, A. A.; Martin, J. H.; Miller, C. A. p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron 1995, 14, 67-78.
10. Dong, C.; Yang, D. D.; Wysk, M.; Whitmarsh, A. J.; Davis, R. J.; Flavell, R. A. Defective T cell differentiation in the absence of JNk1. Science 1998, 282, 2092-2095.
11. Yang, D. D.; Conze, D.; Whitmarsh, A. J.; Barrett, T.; Davis, R. J.; Rincon, M.; Flavell, R. A. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998, 9, 575-585.
12. Sabapathy, K.; Hu, Y.; Kallunki, T.; Schreiber, M.; David, J. P.; Jochum, W.; Wagner, E. F.; Karin, M. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 1999, 9, 116-125.
13. Tournier, C.; Hess, P.; Yang, D. D.; Xu, J.; Turner, T. K.; Nimnual, A.; Bar-Sagi, D.; Jones, S. N.; Flavell, R. A.; Davis, R. J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000, 288, 870-874.
14. Yang, D. D.; Kuan, C. Y.; Whitmarsh, A. J.; Rincon, M.; Zheng, T. S.; Davis, R. J.; Rakic, P.; Flavell, R. A. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1897, 389, 865-870.
15. Lin, A. Activation of the JNK signaling pathway: Breaking the brake on apoptosis. Bioessays 2003, 25, 17-24.
16. Manning, A. M.; Davis, R. J. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discovery 2003, 2, 554-565.
17. Bennett, B. L.; Sasaki, D. T.; Murray, B. W.; O'Leary, E. C.; Sakata, S. T.; Xu, W.; Leisten, J. C.; Motiwala, A.; Pierce, S.; Satoh, Y.; Bhagwat, S. S.; Manning, A. M.; Anderson, D. W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A 2001, 98, 13681-13686.
18. Kennedy, N. J.; Davis, R. J. Role of JNK in tumor development. Cell Cycle 2003, 2, 199-201.
19. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371, 199-204.
20. Scapin, G.; Patel, S. B.; Lisnock, J.; Becker, J. W.; LoGrasso, P. V. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem. Biol. 2003, 10, 705-712.
21. Dumas, J. Protein kinase inhibitors: emerging pharmacophores 1997-2000. Expert Opin. Ther. Pat. 2001, 11, 405-429.
22. Cremlyn, R.; Ellis, L.; Pinney, A. Chlorosulfonation of N-benzyl carboxamides. Phosphorus, Sulfur Silicon Relat. Elem. 1989, 44, 167-175.
23. Wityak, J.; Fevig, J. M.; Jackson, S. A.; Johnson, A. L.; Mousa, S. A.; Parthasarathy, A.; Wells, G. J.; DeGrado, W. F.; Wexler, R. R. Synthesis and antiplatelet activity of DMP 757 analogues. Bioorg. Med. Chem. Lett. 1895, 5, 2097-2100.
24. Huang, J.; Widlanski, T. S. Facile synthesis of sulfonyl chlorides. Tetrahedron Lett. 1892, 33, 2657-2660.
25. Reynolds, R. C.; Crooks, P. A.; Maddry, J. A.; Akhtar, M. S.; Montgomery, J. A.; Secrist, J. A., III Synthesis of thymidine dimers containing internucleoside sulfonate and sulfonamide linkages. J. Org. Chem. 1992, 57, 2983-2985.
26. Raju, B.; Wu, C.; Kois, A.; Verner, E.; Okun, I.; Stavros, F.; Chan, M. F. Thiophenesulfonamides as endothelin receptor antagonists. Bioorg. Med. Chem. Lett. 1996, 6, 2651-2656.
27. Garro-Helion, F.; Merzouk, A.; Guibe, F. Mild and selective palladium(0)-catalyzed deallylation of allylic amines. Allylamine and diallylamine as very convenient ammonia equivalents for the synthesis of primary amines. J. Org. Chem. 1993, 58, 6109-6113.
28. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2001, 44, 235-249.
29. Katritzky, A. R.; Oniciu, D. C.; Ghiviriga, I. The Mitsunobu reaction: an alternative synthesis of 1-(primary alkyl)benzotriazoles. Synth. Commun. 1997, 27, 1613-1621.
30. Legos, J. J.; McLaughlin, B.; Skaper, S. D.; Strijbos, P. J.; Parsons, A. A.; Aizenman, E.; Herin, G. A.; Barone, F. C.; Erhardt, J. A. The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur. J. Pharmacol. 2002, 447, 37-42.